A Discussion on the Company’s Decision Making Process‚ Group Behavior and Organizational Structure Abstract Merck is a pharmaceutical and medical researching company that is dealing with managerial challenges in their daily business operations. Their background and their issues regarding the matter will then help one understand how the actual picture of the real accounts of the managerial decision processes that happen to actual multinational company operations. Having been
Premium Corporation Business Company
EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug
Merck‚ the FDA‚ and the VIOXX Recall MBA 520-D4C2 Ethics & Leadership in a Global Environment April 22‚ 2012 Merck and Vioxx Recall Did Merck act in social and ethical manner? In 2005‚ Merck was ranked fourth in sales among pharmaceutical companies. Merck had released the drug Vioxx‚ for treating Osteoarthritis in late 1990. Merck as a company has a reputation of being one of the most ethical and
Premium Marketing Brand Management
In the year 2000‚ Merck produced a controversial product called Vioxx. Four years later it gained worldwide attention because of the drug’s potential cardiovascular risks. This was detrimental to the company’s reputation because it was alleged Merck knowingly distributed Vioxx despite its risk. Both Barbara Martinez and Anne W. Mathews of the Wall Street Journal wrote articles into the investigation of Vioxx. Their article suggests Merck knew the dangers of Vioxx at an early stage of its clinical
Premium Clinical trial
positively affect the company’s image with the public. However‚ if they did not decide to develop the drug‚ it could negatively affect their image especially if the media would be aware of it. Think about the decision in terms of the CSR pyramid. Did Merck have an ethical obligation to proceed with development of the drug? Would it matter if the drug had only a small chance to cure river blindness? Does it depend on how close the company was to achieving a cure‚ or how sure they were that they could
Premium Integrity Pharmaceutical drug Onchocerciasis
Introduction and Situational Analysis Merck and River Blindness ethical dilemma is whether to pursue research that may or may affect the profits‚ or to choose a safer choice and go for profit rather than researching the drug. The outcome from researching the drug could possibly lead to healing the deadly and dangerous disease known as River Blindness. This drug is known to kill the parasite that has caused the disease. The problem with this situation was that the consumers of the drug could not pay
Premium Pharmacology Medicine Ethics
Pricing objectives and pricing methods in the services sector George J. Avlonitis and Kostis A. Indounas Department of Marketing and Communication‚ Athens University of Economics and Business‚ Athens‚ Greece Abstract Purpose – The purpose of this research paper is to explore the pricing objectives that service companies pursue along with the pricing methods that they adopt in order to set their prices. Design/methodology/approach – An extensive review of the literature revealed the complete
Premium Pricing Marketing
Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Merck’s highest priority areas are Alzheimer’s disease‚ atherosclerosis‚ cardiovascular disease‚ diabetes‚ novel vaccines‚ obesity‚ oncology‚ pain and sleep disorders. In addition‚ and importantly for licensing‚ the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics‚ antifungals‚ antivirals (HCV and HIV)‚ asthma‚ COPD‚ neurodegeneration‚ ophthalmology
Premium RNA Protein Immune system
Elektra Electronics Company is a business division of a mid-sized company focused on manufacturing and selling a high quality consumer electronic device through high-end marketing channels such as specialty shops and exclusive department stores. These specialty outlets advise and educate customers about the desirable features of different electronic devices. Elektra charges on average 500 per unit to its distributors‚ who mark it up to 899 when selling to retail customers. After many years of high
Premium Marketing Retailing Cost
3rd‚ 2014 Case 5: Merck‚ the FDA‚ and the Vioxx Recall Section I Merck was one of the world’s leading pharmaceutical firms. The company ranked 4th I sales after Pfizer and Johnson & Johnson and it ranked 5th in assets and market value. Merck ranked 1st in profits‚ earning $7.33 billion on $30.78 billion in sales. In 2006‚ Merck faced major challenges with their once best selling prescription painkillers‚ Vioxx which was pulled off the market in September of 2004 after Merck learned it increased
Free Pharmacology Food and Drug Administration